In this situation, the main idea is that some drugs used for inflammatory conditions can directly affect male fertility by altering sperm production. Sulfasalazine is well known to cause reversible decreases in sperm count and motility. This effect is usually noticeable enough to impact fertility, and it typically improves after stopping the medication. Because of that, it’s the one you would hold if a patient is actively trying to conceive. The sulfapyridine component in sulfasalazine is largely responsible for the impact on spermatogenesis, and the change is generally reversible with discontinuation. Other options don’t have the same proven association with reduced sperm production. Hydroxychloroquine is considered safe for male fertility; methotrexate is primarily a concern for pregnancy in women, though it’s teratogenic, and leflunomide has a long elimination time and requires a separate washout process if fertility is desired, but sulfasalazine is the classic, direct issue for male fertility.

Hepatitis B reactivation is the boxed warning clinicians emphasize with rituximab. By depleting B cells, rituximab can disrupt immune control of latent HBV in people who have been exposed, leading to reactivation that can progress to fulminant hepatitis, hepatic failure, and even death. Because of this, every patient should be screened for HBV before starting therapy (check HBsAg and anti-HBc). If there’s current or prior infection, antiviral prophylaxis (for example, entecavir or tenofovir) is recommended and continued for a period after completing rituximab. In those with resolved infection, prophylaxis or careful monitoring may be considered based on risk. PML is another serious risk associated with rituximab, but the strongest, most emphasized boxed warning relates to HBV reactivation. Infusion-related reactions are common and managed with standard precautions, while hypoglycemia is not a typical Rituximab concern.

In late-stage osteoarthritis, the bone just under the damaged cartilage adapts to the abnormal joint mechanics by increasing remodeling that leads to thickening and densification—subchondral sclerosis. Along the joint margins, osteophytes or bone spurs form as the skeleton attempts to stabilize the joint and distribute loads more effectively. These two changes—subchondral sclerosis and osteophyte formation—are hallmark features of late OA subchondral bone, visible on imaging as a denser subchondral plate and bony outgrowths at the joint margins. Other patterns don’t fit OA as well. Decreased bone turnover is more typical of osteoporosis, not the sclerosis seen in OA. Poor bone mineralization points to metabolic bone diseases like osteomalacia. And while OA can involve altered load and potential microdamage, the characteristic late-stage pattern emphasizes increased density and osteophyte development rather than greater bone fragility or deformability.

CMC stands for carpometacarpal—the joints where the carpal bones of the wrist meet the bases of the metacarpal bones in the hand. This is the standard way the abbreviation is used in anatomy and in braces or clinical notes. A hyphenated form like carpo-metacarpal is a variant spelling, but carpometacarpal is the common, widely accepted term. Adding “joint capsule” turns the phrase into a description of a structure around the joint rather than the name of the joint itself, and carpo-metacondylar points to a nonstandard articulation in the hand. So the best choice is carpometacarpal.